DNMT1 and myelodysplastic syndrome: Additionally, previous studies have shown that treatment with Decitabine, a pan-DNMT inhibitor, causes anemia by inducing DNA damage, cell cycle arrest, and apoptosis of the erythroid progenitor cells in patients with myelodysplastic syndrome and acute myeloid leukemia [43–46].